{"id":816700,"date":"2025-02-24T10:31:55","date_gmt":"2025-02-24T15:31:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-appoints-kevin-springman-as-vice-president-of-sales\/"},"modified":"2025-02-24T10:31:55","modified_gmt":"2025-02-24T15:31:55","slug":"avadel-pharmaceuticals-appoints-kevin-springman-as-vice-president-of-sales","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-appoints-kevin-springman-as-vice-president-of-sales\/","title":{"rendered":"Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales"},"content":{"rendered":"
\n

DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets.<\/p>\n

“We\u2019re delighted to welcome Kevin to Avadel \u2013 he\u2019s a great addition to our team with the deep experience to help us drive success at this important time,” said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. “Kevin\u2019s expertise and proven track record in building and leading specialized sales teams will be invaluable as we continue building momentum behind the launch of LUMRYZ, our FDA-approved innovative treatment for narcolepsy.\u201d<\/p>\n

Avadel is executing a comprehensive commercial strategy to increase demand for LUMRYZ\u2122, with the goal of enhancing the experience for both patients and providers and unlocking the billion-dollar market potential of LUMRYZ. Avadel\u2019s commercial launch in narcolepsy and ongoing progress in its investigational, Phase 3 trial in idiopathic hypersomnia (IH) positions the company to solidify its leadership in the sleep space and transform care for patients with sleep disorders.<\/p>\n

Mr. Springman brings more than 25 years of sales, marketing and market access leadership to Avadel. He started his sales career at AstraZeneca, where he spent 22 years, rising to become Franchise Head, Infectious Disease. Later, Mr. Springman was Vice President, Head of Immunology & Rare Disease Franchises at Sobi \u2013 North America. After that, he was President of the Americas at Albireo Pharma, where he helped build the company\u2019s commercial infrastructure and led a specialized sales and market access team. Most recently, Mr. Springman was an independent consultant to rare disease and specialty pharma companies.<\/p>\n

\u201cI\u2019m excited to join Avadel at such a pivotal moment in the launch of LUMRYZ,\u201d said Mr. Springman. \u201cAvadel has an exceptional opportunity with LUMRYZ, built on a strong foundation in sleep medicine. I look forward to optimizing our sales strategy and execution to drive LUMRYZ\u2019s continued growth and market leadership while improving patients\u2019 lives.\u201d<\/p>\n

Avadel is intent on further strengthening its executive team and is progressing its search for a new leader of its commercial organization.<\/p>\n

\n About LUMRYZ<\/strong>
\n \u2122<\/strong>
\n (sodium oxybate) for extended-release oral suspension<\/strong>
\n \u00a0<\/strong>\n <\/p>\n

LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.\u202f\u202f<\/p>\n

The FDA approval of LUMRYZ was supported by results from REST-ON, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial in adults with narcolepsy. LUMRYZ demonstrated statistically significant and clinically meaningful improvements in the three co-primary endpoints: EDS, clinicians\u2019 overall assessment of patients\u2019 functioning (CGI-I) and cataplexy attacks, for all three evaluated doses when compared to placebo.\u202f\u202f<\/p>\n

With its approval, the FDA also granted seven years of Orphan Drug Exclusivity to LUMRYZ for the treatment of cataplexy or EDS in adults with narcolepsy due to a finding of clinical superiority of LUMRYZ relative to currently available oxybate treatments. In particular, the FDA found that LUMRYZ makes a major contribution to patient care over currently available, twice-nightly oxybate products by providing a once-nightly dosing regimen that avoids nocturnal arousal to take a second dose.<\/p>\n

\n About Avadel Pharmaceuticals plc<\/strong>\n <\/p>\n

Avadel Pharmaceuticals\u00a0plc\u00a0(Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel\u2019s commercial product, LUMRYZ\u2122, was approved by the\u00a0U.S. Food & Drug Administration\u00a0(FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit\u00a0www.avadel.com<\/a><\/strong>.<\/p>\n

\n IMPORTANT SAFETY INFORMATION<\/strong>\n <\/p>\n\n\n
\n WARNING: Taking LUMRYZ\u2122 (sodium oxybate) with other central nervous system (CNS) depressants, such as medicines used to make you fall asleep, including opioid analgesics, benzodiazepines, sedating antidepressants, antipsychotics, sedating anti-epileptic medicines, general anesthetics, muscle relaxants, alcohol or street drugs, may cause serious medical problems, including trouble breathing (respiratory depression), low blood pressure (hypotension), changes in alertness (drowsiness), fainting (syncope) and death.<\/strong><\/p>\n

The active ingredient of LUMRYZ (sodium oxybate) is a form of gamma hydroxybutyrate (GHB), a controlled substance. Abuse or misuse of illegal GHB alone or with other CNS depressants (drugs that cause changes in alertness or consciousness) have caused serious side effects. These effects include seizures, trouble breathing (respiratory depression), changes in alertness (drowsiness), coma and death. Call your doctor right away if you have any of these serious side effects.<\/strong><\/p>\n

Because of these risks, LUMRYZ is available only by prescription and filled through certified pharmacies in the LUMRYZ REMS. You must be enrolled in the LUMRYZ REMS to receive LUMRYZ. Further information is available at www.LUMRYZREMS.com or by calling 1-877-453-1029.<\/strong>\n <\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n

\n INDICATIONS<\/strong>
\n
LUMRYZ\u00a0(sodium oxybate) for extended-release oral suspension is a prescription medicine used to treat the following symptoms in patients 7 years of age and older with narcolepsy:<\/p>\n